Skip to content
Peptide research

Rigin

Also known as Palmitoyl Tetrapeptide-7
Category
Specialized Research
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

Rigin is a synthetic tetrapeptide (Gly-Gln-Pro-Arg) sold as an immune modulator for phagocytosis, cytokine balance, and wound healing. The case rests mostly on mechanism and animal data, human evidence is low confidence, and claims of antimalarial or antifungal action are speculative. Human safety data is largely absent, with a theoretical risk of overstimulated immunity in autoimmune disease. Not FDA-approved; supply is unregulated research-grade product.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Phagocytosis stimulation and innate immune enhancement

    Low

    In vitro and animal data show tuftsin-like phagocytic activity, no human studies conducted.

  • Cytokine modulation — IL-1, IL-6, and TNF regulation

    Speculative

    IL-6 reduction claim comes from cosmetic industry data, no controlled studies confirm it.

  • Anti-inflammatory skin protection and collagen preservation

    Speculative

    Human studies used peptide blends only, individual contribution to skin protection unproven.

Evidence limits

Evidence Level
Preclinical

Rigin has a modest but growing evidence base. For systemic immunomodulatory applications, evidence is entirely preclinical: in vitro phagocytosis assays, cytokine modulation studies in mouse macrophages and human monocytes, and in vivo malaria protection studies in mice. No clinical trials have evaluated systemic rigin administration in humans. For topical anti-aging use, palmitoyl tetrapeptide-7 has been tested in several small clinical studies as part of multi-ingredient formulations, showing reductions in wrinkles, improvements in elasticity, and increases in dermal density and collagen. However, no placebo-controlled RCT has isolated palmitoyl tetrapeptide-7 as the sole active ingredient. Safety data is favorable: HRIPT in 52 subjects showed no irritation or sensitization, and clinical studies report no adverse reactions at standard cosmetic concentrations (0.01-2%).

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Unknown systemic safety profile

    High
  • Limited long-term topical safety data

    Moderate
  • Contact dermatitis (topical palmitoyl tetrapeptide-7)

    Low
  • Skin irritation when combined with retinoids

    Theoretical
  • Potential immunostimulatory risk in autoimmune conditions

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.